NovoCure Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

NovoCure wird ein jährliches Gewinn- und Umsatzwachstum von 5.1% bzw. 9.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 6.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -218.9% betragen.

Wichtige Informationen

3.7%

Wachstumsrate der Gewinne

4.3%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	18.5%
Wachstumsrate der Einnahmen	9.6%
Zukünftige Eigenkapitalrendite	-49.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	06 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

BOVESPA:N2VC34 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	683	-147	-106	N/A	7
12/31/2025	616	-154	-64	-2	8
12/31/2024	580	-146	-75	-26	8
6/30/2024	550	-169	-104	-67	N/A
3/31/2024	526	-193	-121	-88	N/A
12/31/2023	509	-207	-100	-73	N/A
9/30/2023	504	-197	-89	-62	N/A
6/30/2023	508	-174	-46	-21	N/A
3/31/2023	522	-141	-5	18	N/A
12/31/2022	538	-93	9	31	N/A
9/30/2022	543	-82	20	49	N/A
6/30/2022	545	-68	24	51	N/A
3/31/2022	538	-59	36	61	N/A
12/31/2021	535	-58	59	83	N/A
9/30/2021	546	-27	106	122	N/A
6/30/2021	545	-5	113	128	N/A
3/31/2021	527	12	99	115	N/A
12/31/2020	494	20	84	99	N/A
9/30/2020	450	19	40	53	N/A
6/30/2020	409	12	24	37	N/A
3/31/2020	380	9	22	33	N/A
12/31/2019	351	-7	16	27	N/A
9/30/2019	322	-27	27	36	N/A
6/30/2019	294	-41	19	27	N/A
3/31/2019	269	-55	4	11	N/A
12/31/2018	248	-64	-9	-2	N/A
9/30/2018	232	-59	-28	-22	N/A
6/30/2018	217	-59	-32	-25	N/A
3/31/2018	194	-64	N/A	-23	N/A
12/31/2017	177	-62	N/A	-33	N/A
9/30/2017	154	-73	N/A	-44	N/A
6/30/2017	125	-95	N/A	-80	N/A
3/31/2017	105	-114	N/A	-104	N/A
12/31/2016	83	-132	N/A	-108	N/A
9/30/2016	65	-143	N/A	-120	N/A
6/30/2016	52	-135	N/A	-109	N/A
3/31/2016	41	-124	N/A	-102	N/A
12/31/2015	33	-112	N/A	-100	N/A
9/30/2015	25	-102	N/A	-91	N/A
6/30/2015	20	-94	N/A	-87	N/A
3/31/2015	18	-86	N/A	-83	N/A
12/31/2014	15	-81	N/A	-74	N/A
12/31/2013	10	-77	N/A	-53	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: N2VC34 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: N2VC34 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: N2VC34 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: N2VC34Die Einnahmen des Unternehmens (9.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt BR (7.5% pro Jahr).

Hohe Wachstumseinnahmen: N2VC34Die Einnahmen des Unternehmens (9.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: N2VC34 wird voraussichtlich in 3 Jahren unrentabel sein.

NovoCure Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Novocure Announces CEO Changes, Effective January 1, 2025

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

Novocure Announces Resignation of Todd Longsworth as General Counsel

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken